ZURICH (Reuters) - Novartis has not decided what to do with its Sandoz generics unit after announcing a strategic review of the business last year, its chief executive said on Monday.
"No decision has been taken on Sandoz, we continue to evaluate the options," Vas Narasimhan said at the J.P. Morgan Healthcare conference. He also said the Swiss drugmaker continued to look for value-creating bolt-on acquisitions.